Market Cap Crosses Rs 1 Lakh Crore: India's Fourth-Largest Pharma Company's Stock Rallies Over 8% on Improved Margins

Mankind Pharma has been reshaping its portfolio towards chronic therapies, branded specialty products and international markets, supported by the Bharat Serums and Vaccines platform. The company’s September 2026 quarter reflects stronger operating leverage, with profit growth outpacing sales growth and margins expanding.

Net sales for the quarter ended September 2026 rose 17.33 per cent YoY to Rs 4,337.86 crore. Sales were also up 7.62 per cent QoQ from Rs 4,030.59 crore in the June quarter. Total expenditure increased at a relatively slower 14.08 per cent YoY to Rs 3,166.61 crore, helping profit before interest, depreciation and Tax excluding other income rise 27.13 per cent to Rs 1,171.25 crore.

The operating margin excluding other income improved to 27 per cent from 24.92 per cent a year earlier, an expansion of 208 basis points. Profit after tax rose 37.57 per cent YoY to Rs 712.44 crore, while the net profit margin improved to 16.42 per cent from 14.01 per cent in the corresponding quarter last year. Adjusted earnings per share increased 39.03 per cent YoY to Rs 17.23.

The result extends the operating recovery seen in the June quarter, when the company reported improving growth in domestic chronic therapies, specialty products under Bharat Serums and Vaccines, and international business. In the June quarter, domestic business excluding consumer healthcare grew 11 per cent, while exports rose 29 per cent. Management has identified cardiac, anti-diabetes, respiratory and fertility-led specialty products as key portfolio priorities.

The sharper profit growth is particularly relevant after the BSV acquisition raised borrowing costs and brought a more specialised product mix into the group. Net debt had declined to Rs 3,377 crore as of June 30, 2026, from Rs 3,932 crore at March 31, 2026. Input-cost and currency movements remain important variables, however, as management has indicated that higher commodity prices and a stronger dollar could affect gross margins in subsequent quarters.

At 10:15 a.m. on October 27, 2026, Mankind Pharma shares were trading at Rs 2,494.95. The stock was up 8.38 per cent from the previous close of Rs 2,302.00. At this level, the share price was about 4.7 per cent below its 52-week high of Rs 2,618.15, while remaining above the 52-week low of Rs 1,922.45. The company’s market capitalisation stood at about Rs 95,083 crore. 

What This Means for Investors

The September-quarter performance supports the view that Mankind’s portfolio upgrade is translating into better earnings conversion. Revenue growth of 17.33 per cent was accompanied by a 208-basis-point improvement in operating margin excluding other income, allowing profit after tax to grow faster than sales. Continued progress in chronic therapies, BSV’s fertility and women’s health franchises, and international launches could further improve the business mix. Deleveraging after the BSV acquisition also strengthens financial flexibility.

The development is supportive for the investment case because it demonstrates that margin expansion and debt reduction can occur alongside growth. However, sustaining this trend is more important than a single quarter’s outcome. Consumer healthcare recovery, the pace of acute-therapy improvement and the execution of specialty launches remain key operating tests. At 42.4 times trailing twelve-month earnings and 22.53 times enterprise value to trailing twelve-month earnings before interest, tax, depreciation and amortisation, the valuation leaves limited room for a prolonged slowdown in growth or margins.

Disclaimer: The article is for informational purposes only and not investment advice.